Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human interleukin-2 (125Ala)
- Development stage
- Unknown
- Lead developer
- Beijing SL Pharmaceutical
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intra-arterial, Intraperitoneal, Intratumoral, Intravenous, Subcutaneous
01
Overview
Xinji Er (recombinant human interleukin-2 (125Ala)) is an immunomodulatory cytokine developed and manufactured by Beijing SL Pharmaceutical. It is a recombinant human interleukin-2 (IL-2) analogue in which the cysteine residue at position 125 is substituted with alanine (C125A) to improve specific activity and thermal stability. Xinji Er acts as an agonist of the interleukin-2 receptor (IL-2R) complex, promoting the proliferation and activation of cytotoxic T cells, natural killer (NK) cells, and regulatory T (Treg) cells. In China, it is approved for the treatment of various malignancies (including renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, rectal cancer, lymphoma, and lung cancer), control of malignant pleural effusion and ascites, and the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and Sjögren's syndrome, as well as certain infectious diseases and immunodeficiencies.
- Brand names
- Xinji Er
- Other names
- 125Ala IL-2125AlaIL-2Xinji'errecombinant human interleukin-2 (125Ala) injection重组人白介素-2(125Ala)重组人白介素-2（125Ala）重组人白细胞介素-2(125Ala)注射液
02
Targets
IL-2RA (Interleukin-2 receptor subunit alpha)IL2RB (IL-2 receptor beta chain)IL2RG (Interleukin-2 receptor gamma subunit)IL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on recombinant human interleukin-2 (125Ala).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human interleukin-2 (125Ala).